EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Treatment with a Cholecystokinin Receptor Antagonist, Proglumide, Improves Efficacy of Immune Checkpoint Antibodies in Hepatocellular Carcinoma

Narayan Shivapurkar, Martha D Gay, Aiwu Ruth He, Wenqiang Chen, Shermineh Golnazar, Hong Cao, Tetyana Duka, Bhaskar Kallakury, Sona Vasudevan iD, Jill P Smith iD

International Journal of Molecular Sciences · 2023

DOI: 10.3390/ijms24043625 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Narayan Shivapurkar und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Georgetown University, Washington, DC 20007, USA. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Proglumide, Receptors, Cholecystokinin. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, American Association For Cancer Research, United States Department of Defense.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hepatocellular carcinoma (HCC) is the third leading cause of cancer-associated deaths worldwide. Treatment with immune checkpoint antibodies has shown promise in advanced HCC, but the response is only 15–20%. We discovered a potential target for the treatment of HCC, the cholecystokinin-B receptor (CCK-BR). This receptor is overexpressed in murine and human HCC and not in normal liver tissue. Mice bearing syngeneic RIL-175 HCC tumors were treated with phosphate buffer saline (PBS; control), proglumide (a CCK-receptor antagonist), an antibody to programmed cell death protein 1 (PD-1Ab), or the combination of proglumide and the PD-1Ab. In vitro, RNA was extracted from untreated or proglumide-treated murine Dt81Hepa1-6 HCC cells and analyzed for expression of fibrosis-associated genes. RNA was also extracted from human HepG2 HCC cells or HepG2 cells treated with proglumide and subjected to RNA sequencing. Results showed that proglumide decreased fibrosis in the tumor microenvironment and increased the number of intratumoral CD8+ T cells in RIL-175 tumors. When proglumide was given in combination with the PD-1Ab, there was a further significant increase in intratumoral CD8+ T cells, improved survival, and alterations in genes regulating tumoral fibrosis and epithelial-to-mesenchymal transition. RNAseq results from human HepG2 HCC cells treated with proglumide showed significant changes in differentially expressed genes involved in tumorigenesis, fibrosis, and the tumor microenvironment. The use of the CCK receptor antagonist may improve efficacy of immune checkpoint antibodies and survival in those with advanced HCC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsProglumideReceptors, CholecystokininImmune Checkpoint InhibitorsAnimalsMiceCholecystokininFibrosis

Stichwörter der Autor:innen

cholecystokinin receptorepithelial-to-mesenchymal transitionhepatocellular carcinomaimmune checkpoint antibodiesproglumidetumor microenvironment

Substanzen

CholecystokininProglumideReceptors, CholecystokininImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Medicine, Georgetown University, Washington, DC 20007, USA.
  • Department of Oncology, Georgetown University Lombardi Comprehensive Cancer Center, Washington, DC 20007, USA.
  • Department of Biochemistry and Molecular & Cellular Biology, Georgetown University, Washington, DC 20057, USA.
  • Department of Pathology, MedStar Georgetown University Hospital, Washington, DC 20007, USA.

ORCID-Profile: Sona Vasudevan, Jill P Smith

Förderung

  • NCI NIH HHS
  • American Association For Cancer Research
  • United States Department of Defense
  • AACR Bayer-Innovation and Discovery
  • NIH/NCI
  • DOD
  • GUMC Dean

Zitieren

APA

Shivapurkar, N., Gay, M. D., He, A. R., Chen, W., Golnazar, S., Cao, H., Duka, T., Kallakury, B., Vasudevan, S., & Smith, J. P. (2023). Treatment with a Cholecystokinin Receptor Antagonist, Proglumide, Improves Efficacy of Immune Checkpoint Antibodies in Hepatocellular Carcinoma. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24043625

Vancouver

Shivapurkar N, Gay MD, He AR, Chen W, Golnazar S, Cao H, et al. Treatment with a Cholecystokinin Receptor Antagonist, Proglumide, Improves Efficacy of Immune Checkpoint Antibodies in Hepatocellular Carcinoma. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24043625

BibTeX
@article{Shivapurkar2023,
  author = {Shivapurkar, Narayan and Gay, Martha D and He, Aiwu Ruth and Chen, Wenqiang and Golnazar, Shermineh and Cao, Hong and Duka, Tetyana and Kallakury, Bhaskar and Vasudevan, Sona and Smith, Jill P},
  title = {Treatment with a Cholecystokinin Receptor Antagonist, Proglumide, Improves Efficacy of Immune Checkpoint Antibodies in Hepatocellular Carcinoma},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  doi = {10.3390/ijms24043625}
}
Kostenlos starten →